Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of MASH. FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. For additional information about Sagimet, please visit .SAN MATEO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.
加州圣马特奥，《环球新闻》--Sagimet生物科学公司（Sagimet, 纳斯达克: SGMT）是一家临床阶段的生物制药公司，致力于开发针对功能异常的新型脂肪酸合酶（FASN）抑制剂，旨在靶向代谢和纤维化途径。公司今天宣布，管理层将参加两个即将举行的投资者会议。
- A fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York at 11:00 a.m. ET / 8:00 a.m. PT on September 10, 2024; and
- A fireside chat at the 2024 Cantor Global Healthcare Conference in New York at 9:10 a.m. ET / 6:10 a.m. PT on September 17, 2024.
- 2014 Cantor全球医疗健康会议将于2024年9月17日上午9:10在纽约举行。
- 董事长将在2024年9月10日上午11:00在纽约的H.C. Wainwright第26届年度全球投资大会进行座谈。
Webcasts of each fireside chat will be available in the Investors & Media section of Sagimet's website at , with archived replays available for 90 days following the live event.
每个座谈会的网络直播将在Sagimet公司的投资者与媒体部分的网站上提供，完整录像将在现场活动结束后90天内保留。
About Sagimet Biosciences
关于世纪医药公司
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of MASH. FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. For additional information about Sagimet, please visit .
世捷生物科技是一家处于临床阶段的生物制品公司，开发旨在靶向因过度产生脂肪酸棕榈酸而导致疾病的不正常代谢途径的新型脂肪酸合成酶（FASN）抑制剂。世捷生物科技的领先药物候选者Denifanstat是一种口服、每日一次的选择性FASN抑制剂，用于治疗MASH。Denifanstat的2期临床试验FASCINATE-2，已经成功完成并取得了积极的结果。有关世捷生物科技的其他信息，请访问该公司的网站。
Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com
联系方式：
Joyce Allaire
生命科学顾问
Jallaire@lifesciadvisors.com
